Fig. 5 | British Journal of Cancer

Fig. 5

From: Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer

Fig. 5

A combination of Gefitinib and IKK inhibitors down-regulate EGFR, Akt, mTOR, ERK and IKKβ/NF-κB signalling pathways and cell proliferation and survival in FaDu cells. a Inhibition of signalling pathways with a combination of Gefitinib and IKK inhibitors in FaDu cells. FaDu cells were treated with DMSO, Gefitinib, CmpdA or a combination for 48 h and phosphorylation status and total protein levels of p65, Akt, S6K and ERK, as well as levels of cleaved caspase-3, were analysed by Western blot. b A combination of Gefitinib and CmpdA induced more caspase activity compared to either single treatment. Cells were treated with DMSO, Gefitinib, CmpdA or a combination as described above for 48 h and caspase activity was measured (*p < 0.05; **p < 0.01). c A combination of Gefitinib and CmpdA significantly inhibited cell proliferation. Cells were seeded in 96-well plates for 24 h and treated with DMSO, Gefitinib, CmpdA or a combination for 48 h as described above. Cell proliferation was determined by the MTS assay (*p < 0.05; **p < 0.01)

Back to article page